320 related articles for article (PubMed ID: 2681128)
1. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
[TBL] [Abstract][Full Text] [Related]
2. Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom.
King A; Boothman C; Phillips I
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():31-45. PubMed ID: 2808214
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of meropenem against clinical isolates obtained in Canada.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():47-55. PubMed ID: 2808216
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
5. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial in vitro-activity of meropenem against 200 clinical isolates in comparison to 11 selected antibiotics.
Lang C; Beuth J; Ko HL; Tunggal L; Pulverer G
Zentralbl Bakteriol; 1992 Dec; 277(4):485-92. PubMed ID: 1303691
[TBL] [Abstract][Full Text] [Related]
7. [In vitro antibacterial activity of meropenem, a new carbapenem: European data].
Debbia EA; Marchese A; Pesce A; Schito GC
New Microbiol; 1995 Oct; 18 Suppl():1S-17S. PubMed ID: 8574928
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of meropenem and interactions with other antibiotics.
Ferrara A; Grassi G; Grassi FA; Piccioni PD; Gialdroni Grassi G
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():239-50. PubMed ID: 2808210
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
10. Ertapenem: a new carbapenem.
Odenholt I
Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
[TBL] [Abstract][Full Text] [Related]
11. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):157-63. PubMed ID: 9327242
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
Bauernfeind A; Jungwirth R; Schweighart S
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of biapenem, a new carbapenem antibiotic.
Clarke AM; Zemcov SJ
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):377-84. PubMed ID: 8354306
[TBL] [Abstract][Full Text] [Related]
14. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I.
Edwards JR; Turner PJ; Wannop C; Withnell ES; Grindey AJ; Nairn K
Antimicrob Agents Chemother; 1989 Feb; 33(2):215-22. PubMed ID: 2655530
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates.
Ravizzola G; Pinsi G; Gonzales R; Colombrita D; Pirali F; Turano A
Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1053-61. PubMed ID: 2620673
[TBL] [Abstract][Full Text] [Related]
17. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
18. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.
Rhomberg PR; Jones RN; Sader HS;
Int J Antimicrob Agents; 2004 Jan; 23(1):52-9. PubMed ID: 14732314
[TBL] [Abstract][Full Text] [Related]
19. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
Klietmann W; Focht J; Nösner K
Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
